BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37549258)

  • 1. Ezh2 promotes mammary tumor initiation through epigenetic regulation of the Wnt and mTORC1 signaling pathways.
    Liu L; Xiao B; Hirukawa A; Smith HW; Zuo D; Sanguin-Gendreau V; McCaffrey L; Nam AJ; Muller WJ
    Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2303010120. PubMed ID: 37549258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
    Chen Q; Zheng PS; Yang WT
    Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
    Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
    EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The roles of EZH2 in cancer and its inhibitors.
    Liu Y; Yang Q
    Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancer of zeste homolog 2 activates wnt signaling through downregulating CXXC finger protein 4.
    Lu H; Sun J; Wang F; Feng L; Ma Y; Shen Q; Jiang Z; Sun X; Wang X; Jin H
    Cell Death Dis; 2013 Aug; 4(8):e776. PubMed ID: 23949225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
    Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
    Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
    Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
    BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
    Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
    Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
    Wu J; Crowe DL
    Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Regulation of Histone Methylation by mTOR Complexes Controls Glioblastoma Tumor Cell Growth via EZH2 and SAM.
    Harachi M; Masui K; Honda H; Muragaki Y; Kawamata T; Cavenee WK; Mischel PS; Shibata N
    Mol Cancer Res; 2020 Aug; 18(8):1142-1152. PubMed ID: 32366675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
    Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
    Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 is involved in silencing of WNT5A during epithelial-mesenchymal transition of colon cancer cell line.
    Tao J; Shi L; Huang L; Shi H; Chen H; Wang Y; Wang T
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2211-2219. PubMed ID: 28748258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAPRE3 as an epigenetic target of EZH2 restricts ovarian cancer proliferation in vitro and in vivo.
    Zhang Y; Liu F; Zheng J; Jiang K; Ai H; Liu L; Mao D
    Exp Cell Res; 2024 Feb; 435(1):113913. PubMed ID: 38199479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
    Nakagawa M; Fujita S; Katsumoto T; Yamagata K; Ogawara Y; Hattori A; Kagiyama Y; Honma D; Araki K; Inoue T; Kato A; Inaki K; Wada C; Ono Y; Yamamoto M; Miura O; Nakashima Y; Kitabayashi I
    Cancer Sci; 2019 Jan; 110(1):194-208. PubMed ID: 30343511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer.
    Hong J; Lee JH; Zhang Z; Wu Y; Yang M; Liao Y; de la Rosa R; Scheirer J; Pechacek D; Zhang N; Xu Z; Curiel T; Tan X; Huang TH; Xu K
    Cancer Res; 2022 Dec; 82(24):4624-4640. PubMed ID: 36222718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.
    Smith HW; Hirukawa A; Sanguin-Gendreau V; Nandi I; Dufour CR; Zuo D; Tandoc K; Leibovitch M; Singh S; Rennhack JP; Swiatnicki M; Lavoie C; Papavasiliou V; Temps C; Carragher NO; Unciti-Broceta A; Savage P; Basik M; van Hoef V; Larsson O; Cooper CL; Vargas Calderon AC; Beith J; Millar E; Selinger C; Giguère V; Park M; Harris LN; Varadan V; Andrechek ER; O'Toole SA; Topisirovic I; Muller WJ
    Nat Commun; 2019 Jul; 10(1):2901. PubMed ID: 31263101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2: not EZHY (easy) to deal.
    Deb G; Singh AK; Gupta S
    Mol Cancer Res; 2014 May; 12(5):639-53. PubMed ID: 24526064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-Regulated Mechanism of EZH2 and KDM6A on SALL4 Modulates Tumor Progression via Wnt/β-Catenin Pathway in Gastric Cancer.
    Ren L; Deng H; Jiang Y; Liu C
    Dig Dis Sci; 2023 Apr; 68(4):1292-1305. PubMed ID: 36877334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis.
    Zhang Y; Tong T
    Biochem Biophys Res Commun; 2014 Oct; 453(1):172-8. PubMed ID: 25264199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.